Skip to main content Skip to main navigation menu Skip to site footer

The Role of MMP-9 rs 3918242 genetic variant in association between MMP-9 serum level with risk factors of acute ischemic stroke

  • Meyvita Silviana ,
  • Dodik Tugasworo ,
  • Amin Husni ,


Background: Increased serum MMP-9 level is known to be biomarker of atherosclerotic events and risk of cerebrovascular disease. Risk factors for acute ischemic stroke are known to be related to serum MMP-9 level. The genetic variant of MMP-9 rs3918242 is known to have a role in serum MMP-9 level. The aim of the study is to determine the role of MMP-9 rs 3918242 genetic variant in association between MMP-9 serum level with risk factors of acute ischemic stroke.

Methods: This was a cross-sectional study with an observational analytic design. 62 subjects of acute ischemic stroke treated at Dr. Kariadi Hospital Semarang from October 2018 to February 2019 were involved in this study. Statistical analysis was assessed by the bivariate test and followed by a logistic regression test.

Results: From 62 subjects in this study, 45 (72.6%) had high serum MMP-9 level. The association between serum MMP-9 level with risk factors of acute ischemic stroke was statistically significant in hypertension, diabetes mellitus, dyslipidemia, obesity, and hyperuricemia. There is a positive correlation of serum MMP-9 level with a number of acute ischemic stroke factors. In multivariate analysis, the most influential variables were obesity and hyperuricemia. CC Genetic Variant has a role in the association between serum MMP-9 level with risk factors of acute ischemic stroke, which are hypertension, diabetes mellitus, dyslipidemia, obesity, and hyperuricemia. Meanwhile, CT genetic variants only play a role in the association of serum MMP-9 levels with obesity and hyperuricemia as the risk factors for acute ischemic stroke,

Conclusion: CC genetic variants with high serum MMP-9 levels are associated with more acute ischemic stroke risk factors than CT genetic variants with high MMP-9 serum levels. Therefore, CC genetic variants have the potential to pose more risk of acute ischemic stroke.


  1. Musuka TD, Wilton SB, Traboulsi M, Hill MD. Diagnosis and management of acute ischemic stroke: speed is critical. CMAJ. 2015;187(12):887-93. doi: 10.1503/cmaj.140355.
  2. Jusuf Y, Lamsudin RA. Basyiruddin, et al. Stroke Guideline 2011. Ed2. Jakarta, Indonesia: Indonesian Neurology Association (PERDOSSI ): Jakarta; 2011. p. 15–58.
  3. Liu X, Zhu R, Li Q, He Z, Association of MMP-9 Gene Polymorphism and Ischemic Stroke: Evidence from A Case-Control Study to A Meta-Analysis. Int J Clin Exp Med. 2016;9(10):18844–52.
  4. Da A, Candal S, Argibay B, Rey RI, Vargas Z, Prado AV, et al. Vectorized Nanodelivery Systems for Ischemic stroke: a concept and a need. J Nanobiotechnology. 2017;23:1–15
  5. Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA, Lo EH, Montaner J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006;37(6):1399-406. doi: 10.1161/
  6. Kurzepa J, Kurzepa J, Golab P, Czerska S, Bielewicz J. The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int J Neurosci. 2014;124(10):707-16. doi: 10.3109/00207454.2013.872102.
  7. Zhong C, Yang J, Xu T, Xu T, Peng Y, Wang A, Wang J, Peng H, Li Q, Ju Z, Geng D, Zhang Y, He J; CATIS Investigators. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. Neurology. 2017;89(8):805-812. doi: 10.1212/WNL.0000000000004257.
  8. Buraczynska K, Kurzepa J, Ksiazek A, Buraczynska M, Rejdak K. Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients. Neuromolecular Med. 2015;17(4):385-90. doi: 10.1007/s12017-015-8367-5.
  9. Zhao JH, Xu YM, Xing HX, Su LL, Tao SB, Tian XJ, Yan HQ, Ji SB. Associations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarction. Genet Mol Res. 2016 Jan 4;14(4):19418-24.
  10. TTabatabaee FAG, Vasudevan R, Heidari F, Khazaei S, Etemad A, Ismail P. Association of MMP-1, 9, 12 and TIMP-1 Gene Polymorphisms in Malaysian Male Hypertensive Subjects. Biomed Res. 2018;29(9):1734–42.
  11. Yang W, Lu J, Yang L, Zhang J. Association of Matrix Metalloproteinase-9 Gene -1562C/T Polymorphism with Essential Hypertension: A Systematic Review and Meta-Analysis. Article. Iran J Public Health. 2015;44(11):1445–52.
  12. Kowluru RA. Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras. Invest Ophthalmol Vis Sci. 2010;51(8):4320-6. doi: 10.1167/iovs.09-4851.
  13. Singh K, Agrawal NK, Gupta SK, Singh K. A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int J Low Extrem Wounds. 2013;12(3):199-204. doi: 10.1177/1534734613493289.
  14. Gao Y, Jiang W, Yan Q, Li Z. Association between IL-6-174G/C and -572G/C Polymorphisms and Risk of Coronary ArteryDisease in A Chinese Population. Int J Clin Exp Pathol. 2016;9(1):282–7.
  15. Zhang Z, Wu X, Cai T, Gao W, Zhou X, Zhao J, Yao J, Shang H, Dong J, Liao L. Matrix Metalloproteinase 9 Gene Promoter (rs 3918242) Mutation Reduces the Risk of Diabetic Microvascular Complications. Int J Environ Res Public Health. 2015;12(7):8023-33. doi: 10.3390/ijerph120708023.
  16. Yi X, Zhou Q, Sui G, Fan D, Zhang Y, Shao M, Han Z, Luo H, Lin J, Zhou J. Matrix metalloproteinase-9 gene polymorphisms are associated with ischemic stroke severity and early neurologic deterioration in patients with atrial fibrillation. Brain Behav. 2019;9(6):e01291. doi: 10.1002/brb3.1291.
  17. Amălinei C, Căruntu ID, Giuşcă SE, Bălan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 2010;51(2):215-28.
  18. Wu P, Hua Y, Tan S, Li M, Shu Y, Fang G. Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease: a preliminary case-control study. Int J Clin Exp Pathol. 2015;8(4):4165-70.
  19. Andrade VL, Fernandes KS, Bosco AA, Tanus-Santos JE, Sandrim VC. Functional polymorphism located in MMP-9 gene promoter is strongly associated with obesity. DNA Cell Biol. 2012;31(6):1054-7. doi: 10.1089/dna.2011.1526.
  20. Mehde AA, Mehdi WA, Yusof F, Raus RA, Zainal Abidin ZA, Ghazali H, Abd Rahman A. Association of MMP-9 gene polymorphisms with nephrolithiasis patients. J Clin Lab Anal. 2018;32(1):e22173. doi: 10.1002/jcla.22173.
  21. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999;105(5):418-23. doi: 10.1007/s004390051124.
  22. Zhang X, Cao X, Xu X, Li A. Correlation between The -1562C/T Polymorphism in The Matrix Metalloproteinase-9 Gene and Hemorrhagic Transformation of Ischemic Stroke. Exp Ther Med. 2015;(9):1043–7.
  23. Montaner J, Fernández-Cadenas I, Molina CA, Monasterio J, Arenillas JF, Ribó M, Quintana M, Chacón P, Andreu AL, Alvarez-Sabín J. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke. 2003 Dec;34(12):2851-5. doi: 10.1161/01.STR.0000098648.54429.1C. Epub 2003 Nov 6. PMID: 14605329.
  24. Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro JM, Oliveira SA, Vicente AM. Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet. 2010;11:40. doi: 10.1186/1471-2350-11-40.
  25. Szczudlik P. Association between The -1562 C/T MMP-9 Polymorphism and Cerebrovascular Disease in A Polish Population. Neurol Neurochir Pol. 2010;(44):350–7.
  26. Nie SW, Wang XF, Tang ZC. Correlations between MMP-2/MMP-9 promoter polymorphisms and ischemic stroke. Int J Clin Exp Med. 2014;7(2):400-4.
  27. Chaudhuri JR, Mridula KR, Umamahesh M, Swathi A, Balaraju B, Bandaru VC. High sensitivity C-reactive protein levels in Acute Ischemic Stroke and subtypes: A study from a tertiary care center. Iran J Neurol. 2013;12(3):92-7.
  28. Xu Y, Wang Y, Zhi J, Qi L, Zhang T, Li X. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. BMC Pharmacol Toxicol. 2017;18(1):28. doi: 10.1186/s40360-017-0132-y.
  29. Yadav SS, Mandal RK, Singh MK, Verma A, Dwivedi P, Sethi R, Usman K, Khattri S. High serum level of matrix metalloproteinase 9 and promoter polymorphism - 1562 C:T as a new risk factor for metabolic syndrome. DNA Cell Biol. 2014;33(11):816-22. doi: 10.1089/dna.2014.2511.
  30. Li Y, et al., Association of Polymorphisms of The Matrix Metalloproteinase 9 Gene with Ischaemic Stroke in A Southern Chinese Population. Cell. Physiol. Biochem. 2018;(49):2188–99.

How to Cite

Silviana, M., Tugasworo, D., & Husni, A. (2021). The Role of MMP-9 rs 3918242 genetic variant in association between MMP-9 serum level with risk factors of acute ischemic stroke. Bali Medical Journal, 10(1), 453–459.




Search Panel